HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial.

Abstract
Previous studies provided inconclusive evidence for the effectiveness of gonadotropin-releasing hormone analogue on ovarian function protection against chemotherapy-induced genotoxicity in premenopausal patients. This study was designed to examine the efficacy of leuprolide acetate on ovarian function preservation in patients with breast cancer. A total of 220 patients were recruited in this prospective clinical trial and were assigned randomly to receive cyclophosphamide-doxorubicin-based chemotherapy only or chemotherapy plus leuprolide acetate. Resumption of menses or premenopausal levels of both follicle-stimulating hormone (FSH) and estradiol (E2) within 12 months after the end of chemotherapy were considered as effective ovarian preservation. A total of 183 patients were considered evaluable (94 in chemotherapy-only group and 89 in chemotherapy plus leuprolide acetate group). At the end of follow-up, 27 patients in chemotherapy group and 15 in chemotherapy plus leuprolide acetate group resumed menses; seven patients in chemotherapy group and 14 in chemotherapy plus leuprolide acetate group restored premenopausal levels of FSH and E2. The median time to resume menses was 9.2 months for patients in chemotherapy plus leuprolide acetate group and was not reached in chemotherapy-only group. In addition, our results demonstrated that age and chemotherapy doses made no significant difference in the occurrence of premature menopause. The leuprolide acetate treatment simultaneously with cyclophosphamide-doxorubicin-based chemotherapy reduced the risk of developing premature menopause in premenopausal patients with breast cancer.
AuthorsGuiping Song, Hui Gao, Zhixiang Yuan
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 30 Issue 3 Pg. 667 ( 2013) ISSN: 1559-131X [Electronic] United States
PMID23904400 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Hormonal
  • Estradiol
  • Doxorubicin
  • Cyclophosphamide
  • Follicle Stimulating Hormone
  • Leuprolide
Topics
  • Adult
  • Antineoplastic Agents, Alkylating (administration & dosage)
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Breast Neoplasms (drug therapy, metabolism)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Estradiol (metabolism)
  • Female
  • Follicle Stimulating Hormone (metabolism)
  • Humans
  • Leuprolide (therapeutic use)
  • Middle Aged
  • Ovary (drug effects, metabolism)
  • Premenopause (drug effects, metabolism)
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: